Quick Answer
PALISADE BIO, INC. reported Total Revenue of $0.00 for fiscal year 2024.
PALISADE BIO, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $0.00 -100.0% |
$250.0K | $0.00 | — | — |
| Revenue (ASC 606) | — | $0.00 -100.0% |
$250.0K | $0.00 | — | — |
| Net Income | -$16.78M -16.2% |
-$14.44M -17.4% |
-$12.30M +13.7% |
-$14.26M +46.4% |
-$26.62M -157.9% |
-$10.32M -23.6% |
| Diluted EPS | -$0.30 +97.1% |
-$10.19 +62.3% |
-$27.01 -63.4% |
-$16.53 +90.3% |
-$169.74 -4462.9% |
-$3.72 |
| Total Assets | $134.34M +1134.8% |
$10.88M -22.6% |
$14.05M -10.9% |
$15.76M +26.0% |
$12.51M +314.4% |
$3.02M -54.1% |
| Cash and Equivalents | $133.38M +1258.2% |
$9.82M -21.0% |
$12.43M +0.4% |
$12.38M +18.0% |
$10.49M +1371.9% |
$713.0K -86.1% |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$94.0K |
| Stockholders Equity | $129.38M +1626.9% |
$7.49M -33.8% |
$11.31M -9.3% |
$12.48M +69.4% |
$7.37M +144.4% |
-$16.60M -99.3% |
| R&D Expense | — | — | — | — | — | $2.02M -50.3% |
| Operating Income | -$18.06M -21.5% |
-$14.86M -13.7% |
-$13.07M +16.9% |
-$15.72M +62.4% |
-$41.85M -350.2% |
-$9.30M -7.7% |
| Shares Outstanding | 159.44M +5658.9% |
2.77M +348.0% |
618,056 -79.0% |
2.94M +933.9% |
284,780 -89.7% |
2.77M -28.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$2.87M | +17.8% | -3.0% |
| Diluted EPS | September 30, 2025 | -$0.38 | +83.6% | +34.5% |
| Total Assets | September 30, 2025 | $6.97M | -25.3% | +4.6% |
| Cash and Equivalents | September 30, 2025 | $5.23M | -35.0% | -3.5% |
| Long-Term Debt | September 30, 2021 | $0.00 | — | — |
| Stockholders Equity | September 30, 2025 | $3.21M | -51.4% | +22.6% |
| R&D Expense | March 31, 2021 | $471.1K | -32.4% | +1.1% |
| Operating Income | September 30, 2025 | -$2.92M | +18.7% | -2.8% |
| Shares Outstanding | September 30, 2025 | 9.12M | +660.9% | +90.0% |
- PALISADE BIO, INC. reported Total Revenue of $0.00 for fiscal year 2024.
- PALISADE BIO, INC. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- PALISADE BIO, INC. reported Revenue (ASC 606) of $0.00 for fiscal year 2024.
- PALISADE BIO, INC. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- PALISADE BIO, INC. reported Net Income of -$16.78 million for fiscal year 2025.
- PALISADE BIO, INC. showed a decrease of -16.2% in Net Income compared to the prior fiscal year.
- PALISADE BIO, INC. reported Diluted EPS of $0.30 per share (loss) for fiscal year 2025.
- PALISADE BIO, INC. showed an increase of +97.1% in Diluted EPS compared to the prior fiscal year.
- PALISADE BIO, INC. reported Total Assets of $134.34 million for fiscal year 2025.
- PALISADE BIO, INC. showed an increase of +1134.8% in Total Assets compared to the prior fiscal year.
- PALISADE BIO, INC. reported Cash and Equivalents of $133.38 million for fiscal year 2025.
- PALISADE BIO, INC. showed an increase of +1258.2% in Cash and Equivalents compared to the prior fiscal year.
- PALISADE BIO, INC. reported Long-Term Debt of $0.00 for fiscal year 2021.
- PALISADE BIO, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- PALISADE BIO, INC. reported Stockholders Equity of $129.38 million for fiscal year 2025.
- PALISADE BIO, INC. showed an increase of +1626.9% in Stockholders Equity compared to the prior fiscal year.
- PALISADE BIO, INC. reported R&D Expense of $2.02 million for fiscal year 2020.
- PALISADE BIO, INC. showed a decrease of -50.3% in R&D Expense compared to the prior fiscal year.
- PALISADE BIO, INC. reported Operating Income of -$18.06 million for fiscal year 2025.
- PALISADE BIO, INC. showed a decrease of -21.5% in Operating Income compared to the prior fiscal year.
- PALISADE BIO, INC. reported Shares Outstanding of 159.44 million shares for fiscal year 2025.
- PALISADE BIO, INC. showed an increase of +5658.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: